CompletedNANCT04838756

A Randomized, Single-blinded, Controlled Trial on the Efficacy of Mammography Screening With Artificial Intelligence - the MASAI Study

Sponsor: Region Skane

Trial Details

Condition	Breast Cancer
Intervention	AI screening modality; Conventional screening modality
Phase	NA
Status	Completed
Participants	100,000
Est. Completion	7 Dec 2024
Last Updated	2 Apr 2026

Primary Outcome

Interval-cancer rate

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: Women eligible for population-based mammography screening. Exclusion Criteria: None.

Trial Sites

Countries

Sweden

View Registry Entry

Related Analysis

MASAI Study Completed: AI-Enhanced Mammography Screening Shows Promise in 100,000-Woman Trial — Implications for Australian Breast Cancer Screening

The MASAI study, involving 100,000 women, has completed evaluation of AI-enhanced mammography screening versus conventional double reading. Results expected in early 2025 could reshape breast cancer screening protocols globally, including Australia's BreastScreen programs.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service